| Nome |
# |
|
The eye involvement in monogenic autoinflammatory diseases: Literature review and update, file e0feeaa7-c0ab-44d2-e053-6605fe0a8db0
|
310
|
|
Diagnostic criteria for adult-onset periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome, file e0feeaa7-6701-44d2-e053-6605fe0a8db0
|
162
|
|
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study, file e0feeaa5-e41a-44d2-e053-6605fe0a8db0
|
120
|
|
null, file e0feeaa6-5543-44d2-e053-6605fe0a8db0
|
120
|
|
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response, file e0feeaa8-c0cc-44d2-e053-6605fe0a8db0
|
115
|
|
Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience, file e0feeaa9-21a4-44d2-e053-6605fe0a8db0
|
79
|
|
Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases, file e0feeaa9-196d-44d2-e053-6605fe0a8db0
|
78
|
|
Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman, file e0feeaa5-6037-44d2-e053-6605fe0a8db0
|
77
|
|
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network, file e0feeaa9-21a2-44d2-e053-6605fe0a8db0
|
77
|
|
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study, file e0feeaa9-1b26-44d2-e053-6605fe0a8db0
|
75
|
|
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes, file e0feeaa9-1fea-44d2-e053-6605fe0a8db0
|
70
|
|
Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases, file e0feeaa8-bf24-44d2-e053-6605fe0a8db0
|
64
|
|
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors, file e0feeaa9-1979-44d2-e053-6605fe0a8db0
|
61
|
|
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease, file e0feeaa9-1b2e-44d2-e053-6605fe0a8db0
|
52
|
|
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683, file e0feeaab-dbe5-44d2-e053-6605fe0a8db0
|
48
|
|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases, file c3dd8963-2407-40af-810b-3e3996e34f62
|
42
|
|
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease, file e0feeaa9-219f-44d2-e053-6605fe0a8db0
|
40
|
|
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement, file e0feeaab-dbe6-44d2-e053-6605fe0a8db0
|
38
|
|
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement, file e0feeaa7-c974-44d2-e053-6605fe0a8db0
|
19
|
|
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network, file 32569ad7-c0e5-47d0-9893-4a3300bdafa4
|
18
|
|
Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry, file 1f06ef97-9cd4-4401-a995-b840c047e9f6
|
8
|
|
Development and implementation of the AIDA International Registry for patients with Behçet's disease, file dd68ef5e-6cc8-4848-be1c-710dd15512e8
|
8
|
|
null, file e0feeaaa-c6b8-44d2-e053-6605fe0a8db0
|
7
|
|
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry, file 8870ff56-1eeb-44a0-a9fc-caad9ad4a6d0
|
4
|
|
Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa, file e0feeaa5-832f-44d2-e053-6605fe0a8db0
|
3
|
|
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study, file e0feeaa6-15b6-44d2-e053-6605fe0a8db0
|
3
|
|
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease, file e0feeaa7-9777-44d2-e053-6605fe0a8db0
|
3
|
|
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease, file e0feeaa7-d472-44d2-e053-6605fe0a8db0
|
3
|
|
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis, file e0feeaa9-1973-44d2-e053-6605fe0a8db0
|
3
|
|
Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry, file bf413407-5148-4ad8-ba11-6942a13b4a22
|
2
|
|
null, file e0feeaa5-6bda-44d2-e053-6605fe0a8db0
|
2
|
|
null, file e0feeaa5-6ec9-44d2-e053-6605fe0a8db0
|
2
|
|
The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study, file e0feeaa5-8545-44d2-e053-6605fe0a8db0
|
2
|
|
Successful use of canakinumab in a patient with resistant Behçet's disease, file e0feeaa5-9da9-44d2-e053-6605fe0a8db0
|
2
|
|
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study, file e0feeaa6-1aa8-44d2-e053-6605fe0a8db0
|
2
|
|
Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms, file e0feeaa7-6828-44d2-e053-6605fe0a8db0
|
2
|
|
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis, file e0feeaa7-6cde-44d2-e053-6605fe0a8db0
|
2
|
|
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients, file e0feeaa7-c0ad-44d2-e053-6605fe0a8db0
|
2
|
|
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease, file e0feeaa7-d470-44d2-e053-6605fe0a8db0
|
2
|
|
The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up, file e0feeaa4-fd2e-44d2-e053-6605fe0a8db0
|
1
|
|
null, file e0feeaa5-2560-44d2-e053-6605fe0a8db0
|
1
|
|
null, file e0feeaa5-6397-44d2-e053-6605fe0a8db0
|
1
|
|
Immunometabolic biomarkers of inflammation in Behçet's disease: Relationship with epidemiological profile, disease activity and therapeutic regimes, file e0feeaa5-8313-44d2-e053-6605fe0a8db0
|
1
|
|
null, file e0feeaa5-8331-44d2-e053-6605fe0a8db0
|
1
|
|
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives, file e0feeaa5-8688-44d2-e053-6605fe0a8db0
|
1
|
|
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome, file e0feeaa5-b09a-44d2-e053-6605fe0a8db0
|
1
|
|
Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's Disease with different organ involvement: a case series, file e0feeaa5-ce48-44d2-e053-6605fe0a8db0
|
1
|
|
Interleukin-1 Inhibition in Behçet's disease, file e0feeaa5-d3c8-44d2-e053-6605fe0a8db0
|
1
|
|
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives, file e0feeaa5-e04c-44d2-e053-6605fe0a8db0
|
1
|
|
null, file e0feeaa5-e428-44d2-e053-6605fe0a8db0
|
1
|
|
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis, file e0feeaa7-b9a2-44d2-e053-6605fe0a8db0
|
1
|
|
Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease, file e0feeaa7-b9a4-44d2-e053-6605fe0a8db0
|
1
|
|
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study, file e0feeaa7-bef4-44d2-e053-6605fe0a8db0
|
1
|
|
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies, file e0feeaa7-c09d-44d2-e053-6605fe0a8db0
|
1
|
|
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab, file e0feeaa7-c09e-44d2-e053-6605fe0a8db0
|
1
|
|
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study, file e0feeaa7-cba3-44d2-e053-6605fe0a8db0
|
1
|
|
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers, file e0feeaa7-d474-44d2-e053-6605fe0a8db0
|
1
|
|
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma, file e0feeaa8-4d18-44d2-e053-6605fe0a8db0
|
1
|
|
Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab, file e0feeaa8-b672-44d2-e053-6605fe0a8db0
|
1
|
|
Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection, file e0feeaa8-bea0-44d2-e053-6605fe0a8db0
|
1
|
|
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases, file e0feeaa8-bf22-44d2-e053-6605fe0a8db0
|
1
|
|
One year in review 2015: Sjögren's syndrome, file e0feeaa9-1dcd-44d2-e053-6605fe0a8db0
|
1
|
|
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683, file e0feeaaa-023a-44d2-e053-6605fe0a8db0
|
1
|
| Totale |
1.751 |